Modeling the polyglutamine aggregation pathway in Huntington's disease: from basic studies to clinical applications

Area of Science:

• Neuroscience
• Genetics
• Biophysics

Background:

• Huntington's disease (HD) is a polyglutamine (polyQ) disorder caused by CAG-trinucleotide repeat expansions.
• Previously, a unifying pathogenic mechanism for polyQ disorders was assumed, but recent findings reveal diverse polyQ protein aggregate structures and toxicities.
• Disease-specific aspects, like repeat-length dependence, influence clinical features and aggregation propensity.

Purpose of the Study:

• To explore genotype-phenotype correlations in polyQ diseases using risk-based stochastic kinetic models.
• To investigate the quantitative link between polyQ aggregation kinetics and clinical data in HD patients.
• To present a mathematical model for predicting the time course of neurodegeneration in HD.

Main Methods:

• Description of two risk-based stochastic kinetic models: cumulative-damage and one-hit models.
• Utilizing repeat-length as an index to model aggregation kinetics and clinical data in HD.
• Re-evaluation of CAG repeat-length correlations with age-of-onset and disease progression rates.

Main Results:

• Models reflect alternative pathways of polyQ aggregation.
• Quantitative connections established between aggregation kinetics and clinical data in HD.
• A mathematical model is presented for precise prediction of HD neurodegeneration time course.

Conclusions:

• Kinetic models offer insights into polyQ disorder pathogenesis.
• Understanding aggregation pathways is crucial for explaining disease mechanisms.
• Mathematical modeling can precisely predict neurodegeneration in HD, aiding in understanding pathogenesis controversies.